CytomX Therapeutics Inc (CTMX) — Capital Reinvestment Ratio
Latest as of March 2023:
0.01x
CytomX Therapeutics Inc (CTMX) has a Capital Reinvestment Ratio of 0.01x as of March 2023, meaning it reinvests 0% of its operating cash flow ($9.35 Million) in capital expenditures ($48.00K). See CytomX Therapeutics Inc (CTMX) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.01x
Capex / Operating Cash Flow
Operating Cash Flow
$9.35 Million
USD
Capital Expenditures
$48.00K
USD
Data as of
Mar 2023
Most recent filing
CytomX Therapeutics Inc Capital Reinvestment Ratio (2014–2020)
This chart tracks CytomX Therapeutics Inc's Capital Reinvestment Ratio across 3 annual periods.
Annual Capital Reinvestment Ratio for CytomX Therapeutics Inc (2014–2020)
Year-by-year Capital Reinvestment Ratio for CytomX Therapeutics Inc from 2014 to 2020. For live market cap and broader valuation context, see CTMX company net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2020 | 0.44x | $5.26 Million | $2.31 Million | ▲ +4698.2% |
| 2017 | 0.01x | $170.37 Million | $1.56 Million | ▼ -82.5% |
| 2014 | 0.05x | $31.80 Million | $1.66 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow